Aripiprazole 2-Month Under Review for Schizophrenia, Bipolar I Disorder
The NDA is supported by data from a phase 1/2 trial that compared the investigational aripiprazole 2-month, long-acting injectable to aripiprazole 1-month depot.
Mood Disorders
Anxiety in Children and Adults Ballooned in US at Start of COVID-19 Pandemic
The authors discuss identifying and treating anxiety disorders in children and adults in primary care during COVID-19.
Trial Evaluating Zuranolone for Postpartum Depression Meets All Endpoints
Zuranolone is an investigational oral neuroactive steroid GABA-A receptor positive allosteric modulator.
Igalmi Sublingual Film Approved for Agitation With Schizophrenia, Bipolar Disorder
The approval was based on data from the phase 3 SERENITY I and II studies that evaluated Igalmi for the acute treatment of agitation associated with schizophrenia and bipolar disorders I and II, respectively.
New Tool May Help Reduce CVD Risk in Patients With Mental Illnesses
A clinical decisions support system provides personalized treatment recommendations on lowering cardiovascular risk factors in patients with schizophrenia, schizoaffective disorder, and bipolar disorder.
People With Schizophrenia at High Risk of Dying From COVID-19
With people who have major psychiatric disorders being more likely to have comorbidities which could lead to worse results concerning COVID-19, researchers using a US database assessed the odds of testing positive for COVID-19, as well as mortality from COVID-19.
Caplyta Approved for Bipolar Depression in Adults
The approval was supported by data from two phase 3 studies that evaluated Caplyta as monotherapy and adjunctive therapy with lithium or valproate in adults with bipolar depression.
The Perception of Physician Cultural Competency and Mental Health Outcomes
This study examines patient preferences for physicians with cultural competency among patients with depression and anxiety.
Legal and Ethical Approaches to a Patient’s Request for an Emotional Support Animal
Psychiatrists and other mental health professionals are increasingly being asked to write letters certifying patients’ and clients’ animals as emotional support animals.
Lybalvi Now Available for Schizophrenia, Bipolar I Disorder
Lybalvi is an atypical antipsychotic comprised of samidorphan co-formulated with olanzapine in a single bilayer tablet.
- Loading...
Loading...
Next post in News
Loading... 
Loading...